|
Market Closed -
Nasdaq
00:00:00 14/11/2026 +03
|
5-day change | 1st Jan Change | ||
| 9.370 USD | +0.64% |
|
-11.35% | -40.24% |
Company Valuation: Monte Rosa Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 949.7 | 368.3 | 282.8 | 426.4 | 1,021 | 800.7 | - | - |
| Change | - | -61.22% | -23.21% | 50.74% | 139.48% | -21.58% | - | - |
| Enterprise Value (EV) 1 | 603.6 | 105.5 | 50.43 | 54.22 | 1,021 | 261.7 | 290.1 | 140.9 |
| Change | - | -82.52% | -52.19% | 7.5% | 1,783.24% | -74.37% | 10.87% | -51.44% |
| P/E | -6.9x | -3.31x | -2.15x | -7.08x | -34.1x | -8.87x | -5.11x | -5.76x |
| PBR | 2.75x | 1.32x | 1.58x | 1.91x | - | 2.12x | 1.78x | 1.57x |
| PEG | - | 0.1x | -0.1x | 0.1x | 0.6x | -0x | -0.1x | 0.5x |
| Capitalization / Revenue | - | - | - | 5.64x | 8.26x | 7.83x | 12.9x | 7.73x |
| EV / Revenue | - | - | - | 0.72x | 8.26x | 2.56x | 4.67x | 1.36x |
| EV / EBITDA | -8.53x | -0.97x | -0.37x | -0.74x | - | -1.73x | -2.37x | -0.81x |
| EV / EBIT | -8.28x | -0.94x | -0.35x | -0.67x | -18.8x | -2.05x | -1.38x | -0.7x |
| EV / FCF | -8.74x | -1x | -0.8x | 1.43x | -37.1x | -3.91x | -2.6x | -2.99x |
| FCF Yield | -11.4% | -99.9% | -125% | 70.1% | -2.69% | -25.6% | -38.4% | -33.5% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.96 | -2.3 | -2.63 | -0.98 | -0.46 | -1.057 | -1.833 | -1.627 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 75.62 | 123.7 | 102.3 | 62.16 | 103.6 |
| EBITDA 1 | -70.75 | -108.6 | -137.1 | -72.99 | - | -151 | -122.4 | -174.9 |
| EBIT 1 | -72.88 | -112.4 | -143.3 | -81.11 | -54.21 | -127.5 | -210.4 | -201.6 |
| Net income 1 | -73.96 | -108.5 | -135.4 | -72.7 | -38.63 | -106.8 | -193.9 | -189.3 |
| Net Debt 1 | -346.1 | -262.8 | -232.4 | -372.1 | - | -539 | -510.5 | -659.8 |
| Reference price 2 | 20.420 | 7.610 | 5.650 | 6.940 | 15.680 | 9.370 | 9.370 | 9.370 |
| Nbr of stocks (in thousands) | 46,506 | 48,399 | 50,062 | 61,436 | 65,118 | 85,450 | - | - |
| Announcement Date | 3/29/22 A | 3/16/23 A | 3/14/24 A | 3/20/25 A | 3/17/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.87x | 2.56x | -1.73x | - | 801M | |
| 17.35x | 6.64x | 12.72x | 1.72% | 66.33B | |
| 32.78x | 8.77x | 28.98x | 0.07% | 60.62B | |
| 38.6x | 6.87x | 20.53x | 0.84% | 55.5B | |
| 44.7x | 6.26x | 29.77x | -.--% | 47.58B | |
| 34.6x | 3.29x | 14.2x | -.--% | 43.69B | |
| -20.57x | 54.42x | -22.49x | -.--% | 37.27B | |
| 36.15x | 8.94x | 23.31x | 0.36% | 36.57B | |
| 40.59x | 7.89x | 26.33x | -.--% | 32.22B | |
| -73.93x | 14x | -75.29x | -.--% | 26.58B | |
| Average | 14.14x | 11.96x | 5.63x | 0.33% | 41B | |
| Weighted average by Cap. | 21.64x | 11.74x | 11.39x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- GLUE Stock
- Valuation Monte Rosa Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
